• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Overcoming acquired resistance following osimertinib administration in EGFR-mutant lung adenocarcinoma.

作者信息

Kaira Kyoichi, Imai Hisao, Kagamu Hiroshi

机构信息

Department of Respiratory Medicine, International Medical Center, Saitama Medical University, Hidaka City, Japan.

出版信息

Transl Lung Cancer Res. 2024 May 31;13(5):1177-1182. doi: 10.21037/tlcr-24-193. Epub 2024 May 27.

DOI:10.21037/tlcr-24-193
PMID:38854932
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11157366/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7a2/11157366/3aa50caef099/tlcr-13-05-1177-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7a2/11157366/3aa50caef099/tlcr-13-05-1177-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b7a2/11157366/3aa50caef099/tlcr-13-05-1177-f1.jpg

相似文献

1
Overcoming acquired resistance following osimertinib administration in EGFR-mutant lung adenocarcinoma.克服表皮生长因子受体（EGFR）突变型肺腺癌患者使用奥希替尼后出现的获得性耐药。
Transl Lung Cancer Res. 2024 May 31;13(5):1177-1182. doi: 10.21037/tlcr-24-193. Epub 2024 May 27.
2
Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report.病例报告：达可替尼克服携带L718Q突变的非小细胞肺癌患者对奥希替尼的耐药性：一例病例报告。
Front Oncol. 2021 Dec 2;11:760097. doi: 10.3389/fonc.2021.760097. eCollection 2021.
3
Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports.获得性EGFR T790M并存及EGFR-TKIs驱动基因耐药阻碍奥希替尼在晚期肺腺癌中的疗效：病例报告
Front Pharmacol. 2022 Apr 6;13:838247. doi: 10.3389/fphar.2022.838247. eCollection 2022.
4
Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas.简要报告：奥希替尼和达可替尼联合使用可减轻 EGFR 突变型肺腺癌的原发性和获得性耐药。
Clin Cancer Res. 2023 Apr 14;29(8):1423-1428. doi: 10.1158/1078-0432.CCR-22-3484.
5
ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in -Mutated Non-Small Cell Lung Cancer.ONO-7475，一种新型的 AXL 抑制剂，抑制了 - 突变非小细胞肺癌对初始 EGFR-TKI 治疗的适应性耐药。
Clin Cancer Res. 2020 May 1;26(9):2244-2256. doi: 10.1158/1078-0432.CCR-19-2321. Epub 2020 Jan 17.
6
Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival.表皮生长因子受体酪氨酸激酶抑制剂耐药后 T790M 阳性肺腺癌的临床特征，重点是脑转移和生存。
Lung Cancer. 2018 Jul;121:12-17. doi: 10.1016/j.lungcan.2018.04.013. Epub 2018 Apr 17.
7
L718Q mutation occurs without T790M mutation in a lung adenocarcinoma patient with acquired resistance to osimertinib.在一名对奥希替尼获得性耐药的肺腺癌患者中，出现了L718Q突变且无T790M突变。
Ann Transl Med. 2019 May;7(9):207. doi: 10.21037/atm.2019.04.37.
8
Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer.用于奥希替尼和塞来昔替尼共递送的纳米颗粒克服非小细胞肺癌奥希替尼获得性耐药。
Acta Biomater. 2021 Jul 15;129:258-268. doi: 10.1016/j.actbio.2021.05.018. Epub 2021 May 25.
9
Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer.解决非小细胞肺癌中表皮生长因子受体酪氨酸激酶抑制剂耐药问题。
Expert Rev Respir Med. 2016;10(5):547-56. doi: 10.1586/17476348.2016.1164603. Epub 2016 Mar 28.
10
Novel CDK12/13 Inhibitors AU-15506 and AU-16770 Are Potent Anti-Cancer Agents in EGFR Mutant Lung Adenocarcinoma with and without Osimertinib Resistance.新型CDK12/13抑制剂AU-15506和AU-16770是治疗伴有或不伴有奥希替尼耐药的EGFR突变型肺腺癌的强效抗癌药物。
Cancers (Basel). 2023 Apr 12;15(8):2263. doi: 10.3390/cancers15082263.

本文引用的文献

1
Osimertinib with or without Chemotherapy in -Mutated Advanced NSCLC.奥希替尼对比含铂化疗用于 - 突变型晚期 NSCLC。
N Engl J Med. 2023 Nov 23;389(21):1935-1948. doi: 10.1056/NEJMoa2306434. Epub 2023 Nov 8.
2
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.Amivantamab 联合化疗加或不加 lazertinib 治疗奥希替尼治疗后进展的 EGFR 突变型晚期 NSCLC：III 期 MARIPOSA-2 研究的主要结果。
Ann Oncol. 2024 Jan;35(1):77-90. doi: 10.1016/j.annonc.2023.10.117. Epub 2023 Oct 23.
3
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.
HERTHENA-Lung01 研究：曲妥珠单抗德鲁替康（HER3-DXd）在表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）和铂类化疗治疗后的表皮生长因子受体突变型非小细胞肺癌中的 II 期研究。
J Clin Oncol. 2023 Dec 10;41(35):5363-5375. doi: 10.1200/JCO.23.01476. Epub 2023 Sep 10.
4
Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study.奥希替尼耐药后第一代或第二代 EGFR-TKI 治疗 EGFR 突变型肺癌的临床疗效和安全性：一项前瞻性探索性研究。
Target Oncol. 2023 Sep;18(5):657-665. doi: 10.1007/s11523-023-00991-5. Epub 2023 Aug 23.
5
Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance.针对 EGFR 突变型非小细胞肺癌的现行治疗策略：从一线治疗到奥希替尼耐药后。
Jpn J Clin Oncol. 2023 Jun 29;53(7):547-561. doi: 10.1093/jjco/hyad052.
6
Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas.简要报告：奥希替尼和达可替尼联合使用可减轻 EGFR 突变型肺腺癌的原发性和获得性耐药。
Clin Cancer Res. 2023 Apr 14;29(8):1423-1428. doi: 10.1158/1078-0432.CCR-22-3484.
7
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance.奥希替尼耐药的表皮生长因子受体突变型非小细胞肺癌患者的治疗策略。
J Hematol Oncol. 2022 Dec 8;15(1):173. doi: 10.1186/s13045-022-01391-4.
8
New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung Cancer.EGFR TKI 耐药的非小细胞肺癌的新策略和新联合治疗。
Curr Treat Options Oncol. 2022 Nov;23(11):1626-1644. doi: 10.1007/s11864-022-01022-7. Epub 2022 Oct 15.
9
Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study.奥希替尼联合贝伐珠单抗对比奥希替尼一线治疗携带 EGFR 突变的非鳞状非小细胞肺癌的随机 II 期研究：WJOG9717L 研究。
J Thorac Oncol. 2022 Sep;17(9):1098-1108. doi: 10.1016/j.jtho.2022.05.006. Epub 2022 May 27.
10
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.第三代表皮生长因子受体（EGFR）和间变性淋巴瘤激酶（ALK）抑制剂：耐药机制与处理
Nat Rev Clin Oncol. 2022 Aug;19(8):499-514. doi: 10.1038/s41571-022-00639-9. Epub 2022 May 9.